Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of isoliquiritin in preparation of medicine for treating osteoporosis

A technology for isoliquiritigenin and osteoporosis, which is applied in the application field of isoliquiritigenin in the preparation of drugs for treating osteoporosis, can solve the problems of troublesome access, high price, side effects and the like, and achieves inhibiting the formation of osteoporosis. , cheap, clear ingredients

Pending Publication Date: 2022-08-05
STOMATOLOGY AFFILIATED STOMATOLOGY HOSPITAL OF GUANGZHOU MEDICAL UNIV
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have shown that bone-forming or dual-action drugs are more effective than anti-resorptive drugs in treating osteoporosis, but these drugs are rare, difficult to obtain, expensive, and have side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of isoliquiritin in preparation of medicine for treating osteoporosis
  • Application of isoliquiritin in preparation of medicine for treating osteoporosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Example 1: Animal experiment

[0013] The steps used in this experiment are: Step 1: Select 30 8-week-old mice and divide them into sham operation group (sham), castration group (OVX), castration group + low concentration group (10mg / kg), castration group Group + medium concentration group (30mg / kg), castration group + high concentration group (50mg / kg), each group has 6 mice to establish a mouse osteoporosis model; Step 2: Isoliquiritigenin is dissolved in carboxymethyl fiber CMC-Na, 0.5 ml of isoliquiritigenin solution was injected into the latter three groups of mice by gavage, and the mice were reared in the same rearing environment. The condition of osteoporosis was judged, and the experimental mice were given continuous gavage for one month. The condition of the osteoporosis in the mice was preliminarily analyzed by micro tomography (Micro CT), and the mice were examined by histopathological examination (HE staining). Slice the affected area to detect the morphol...

Embodiment 2

[0014] Embodiment 2: CCK-8 detects the drug toxicity test of isoliquiritin

[0015] The steps used in this test are:

[0016] Step 1: The configuration of isoliquiritigenin, from the purchased isoliquiritigenin (HPLC>98), weigh 20 mg, use 1 ml of DMSO to prepare 20 mg / ml, and then dilute it with medium to different concentrations of working solution;

[0017] Step 2: Detect the effect of isoliquiritigenin on the proliferation of bone marrow mesenchymal stem cells in vivo, inoculate bone marrow mesenchymal stem cells in 896-well plates at a cell density of 3000 cells / well, and add different concentrations of isoliquiritigenin for stimulation after 24 hours , the concentrations were 6.25, 12.5, 25, and 50, respectively, cultured at 37°, 5% CO2 for 1, 3, and 5 days, and detected with CCK-8.

[0018] Test results such as figure 1 and 2 As shown in the figure, it can be seen from the figure that isoliquiritigenin has a certain promoting effect on cell growth. When the concentrat...

Embodiment 3

[0019] Example 3: In vitro experiments

[0020] The steps used in this experiment are: step 1: obtain and culture bone marrow mesenchymal stem cells; step 2: determine the optimal drug concentration of isoliquiritin according to the results obtained in Example 2; step 3: conduct an osteogenic induction test, MAPK Inhibitors and autophagy (3-MA) ​​inhibitors inhibited related expressions, and then used Western blotting, immunofluorescence staining, alkaline phosphatase staining and quantification, and real-time quantitative PCR (Real-timeqPCR). ), Alizarin red staining was used for verification.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicine, and discloses application of isoliquiritin in preparation of medicine for treating osteoporosis, the molecular formula of isoliquiritin is C21H22O9, the molecular weight is 418.394, the isoliquiritin molecule is one of main components of natural plant liquorice, and the isoliquiritin molecule is natural medicine, easy to obtain, high in safety, low in price and clear in component. Experiments prove that the isoliquiritin can effectively promote osteogenic differentiation potential of BMSCs, can inhibit formation of osteoporosis and promote repair of osteoporotic fractures, and can be used as a medicine for treating osteoporosis and osteoporotic fractures, in addition, some mechanisms of the isoliquiritin for inhibiting osteoporosis are defined, and the isoliquiritin can be used for treating osteoporosis and osteoporotic fractures. And evidence is provided for treating osteoporosis.

Description

technical field [0001] The invention relates to the technical field of medicine, and relates to the application of isoliquiritigenin in the preparation of a medicine for treating osteoporosis. Background technique [0002] With the development of society and the accelerating rate of population aging, osteoporosis has become a common and frequently-occurring disease, which has attracted people's attention in recent years. Osteoporosis (OP) is a systemic metabolic skeletal disease characterized by decreased bone mass and increased bone fragility, often leading to fragility fractures. It is estimated that the number of people suffering from osteoporosis in the world now reaches 200 million, and the annual growth rate is 3.2%, which is much higher than the growth rate of the world population. At present, the treatment methods of osteoporosis mainly include three categories: anti-resorptive, inhibiting osteoclasts; bone formation, stimulating osteoblasts; and simultaneously stim...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7034A61P19/10A61K36/484
CPCA61K31/7034A61P19/10A61K36/484
Inventor 郭吕华苏治康罗涛陈定梁梓添
Owner STOMATOLOGY AFFILIATED STOMATOLOGY HOSPITAL OF GUANGZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com